Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are plasma cell disorders of aging. The landscape of the diagnosis and management of MM and MGUS are rapidly changing. This article provides an updated understanding of the clinical presentation, evaluation, diagnosis, and management of older adults with MM and MGUS. Because most oncology providers are not formally trained in geriatric medicine, geriatricians play a key role in providing oncologists with a broader understanding of patient health status in the hope of improving outcomes for older adults with MM
Purpose: To assess adherence to existing clinical practice standards regarding screening and monitor...
Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen ...
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents...
Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are plasma cell ...
peer reviewedMultiple Myeloma (MM) and other plasma cell malignancies initially present as an asympt...
CITATION: Fazel, F. & Bassa, F. An approach to the diagnosis and management of multiple myeloma. Sou...
Objectives: Tremendous progress has been made in the treatment of multiple myeloma; however, the maj...
Monoclonal gammopathy of undetermined significance (MGUS) is a clonal plasma cell disorder implicate...
Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median ...
Multiple myeloma (MM) is a disease of aging adults, and numerous therapeutic options are available f...
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than...
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 year...
Multiple Myeloma is an incurable disease. It is responsible for 1.8% of all cancers. The median age ...
Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patie...
Monoclonal gammopathy of undetermined significance (MGUS) is a non malignant plasma cell disorder wi...
Purpose: To assess adherence to existing clinical practice standards regarding screening and monitor...
Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen ...
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents...
Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) are plasma cell ...
peer reviewedMultiple Myeloma (MM) and other plasma cell malignancies initially present as an asympt...
CITATION: Fazel, F. & Bassa, F. An approach to the diagnosis and management of multiple myeloma. Sou...
Objectives: Tremendous progress has been made in the treatment of multiple myeloma; however, the maj...
Monoclonal gammopathy of undetermined significance (MGUS) is a clonal plasma cell disorder implicate...
Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median ...
Multiple myeloma (MM) is a disease of aging adults, and numerous therapeutic options are available f...
Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than...
Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 year...
Multiple Myeloma is an incurable disease. It is responsible for 1.8% of all cancers. The median age ...
Multiple myeloma (MM) is a neoplastic disorder affecting elderly people. The treatment for all patie...
Monoclonal gammopathy of undetermined significance (MGUS) is a non malignant plasma cell disorder wi...
Purpose: To assess adherence to existing clinical practice standards regarding screening and monitor...
Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen ...
Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents...